Introduction {#acn3551-sec-0005}
============

Cerebral palsy (CP) is the most common physical disability in childhood and is defined as "a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to nonprogressive disturbances that occurred in the developing fetal or infant brain".[1](#acn3551-bib-0001){ref-type="ref"} Both genetic and environmental factors contribute to the etiology of CP. Recent studies have suggested that a larger number of rare pathogenic genetic variants[2](#acn3551-bib-0002){ref-type="ref"} or pathogenic copy number variations (CNVs)[3](#acn3551-bib-0003){ref-type="ref"} contribute to CP than previously expected.[4](#acn3551-bib-0004){ref-type="ref"} This suggests that "masquerading" genetic diseases can be misdiagnosed as CP.[5](#acn3551-bib-0005){ref-type="ref"} To distinguish these masqueraders from CP is essential for delivering appropriate therapy, prognosis, and genetic counseling. However, there is lack of consensus as to which types of unexplained CP should undergo genetic investigation. A recent meta‐analysis showed that preterm (\<37 weeks) infants had a dramatically increased risk of CP,[6](#acn3551-bib-0006){ref-type="ref"} which suggests that full‐term CP may include more masqueraders than preterm CP. To our knowledge, no genetic studies have specifically focused on full‐term CP. In addition, brain MRI findings are essential for correctly assessing CP by excluding cases caused by apparent environmental factors or cases with other disorders[5](#acn3551-bib-0005){ref-type="ref"} (e.g., porencephaly with *COL4A1* variants[7](#acn3551-bib-0007){ref-type="ref"} and cerebral infarction with *CBS* variants[8](#acn3551-bib-0008){ref-type="ref"}) for which other diagnostic approaches could be used, such as metabolic screening and target sequencing.

In this study, we performed trio whole‐exome sequencing (WES) analysis and array comparative genomic hybridization (aCGH) analysis to identify genetic abnormality, focusing on a subgroup of CP patients isolated by two simple criteria, (1) gestational age of 37 weeks or more and (2) normal or nonspecific brain MRI findings.

Methods {#acn3551-sec-0006}
=======

Participants {#acn3551-sec-0007}
------------

Eight hundred and ninety‐seven cases of cerebral palsy, including spastic CP (hemiplegia/diplegia/triplegia/quadriplegia), ataxic CP, dyskinetic CP, and mixed type CP, were followed at the Takuto Rehabilitation Center for Children, Sendai, Japan between September 1, 1990 and March 31, 2016, as previously reported.[9](#acn3551-bib-0009){ref-type="ref"} Of these cases, 107 families were also recruited for inclusion with at least one family member of the family diagnosed with CP, according to the following criteria: (1) diagnosis of CP without a definitive acquired cause, (2) gestational age of 37 weeks or more, (3) no brain MRI findings that can aid in the diagnosis. Among these cases, 17 patients with both parents were available for trio WES, and written consent was obtained from all individuals (Fig. [1](#acn3551-fig-0001){ref-type="fig"}). This study was approved by the ethics committee of Tohoku University Hospital and Takuto Rehabilitation Center for Children.

![Patient flowchart. CP, cerebral palsy; CPA, cardiac pulmonary arrest.](ACN3-5-538-g001){#acn3551-fig-0001}

Clinical features of case series {#acn3551-sec-0008}
--------------------------------

For each patient, demographic and clinical data were collected from the patient\'s chart, which included gender, age, age at diagnosis, details of pregnancy and birth, gestational weeks, birth weight, head circumference, neonatal events, type of CP, comorbidities, brain MRI findings, and functional classification scores for CP, such as the Gross Motor Function Classification Scale,[10](#acn3551-bib-0010){ref-type="ref"} the Manual Ability Classification System,[11](#acn3551-bib-0011){ref-type="ref"} and the Communication Function Classification System.[12](#acn3551-bib-0012){ref-type="ref"} The types of CP (spastic diplegia, ataxic type, diskinetic type, and mixed type) were classified based on previous reports,[9](#acn3551-bib-0009){ref-type="ref"}, [13](#acn3551-bib-0013){ref-type="ref"} and the brain MRI was performed as previously described.[9](#acn3551-bib-0009){ref-type="ref"}

aCGH analysis {#acn3551-sec-0009}
-------------

Microdeletions and microduplications were evaluated using SurePrint G3 CGH+SNP Microarray Kit 4 × 180K (ISCA) (Agilent Technologies, Santa Clara, CA, USA). CNVs were detected using CytoGenomics 2.5 (Agilent Technologies), and their pathogenicity was assessed using the International Standards for Cytogenomic Arrays (ISCA) database, the Database of Genomic Variants,[14](#acn3551-bib-0014){ref-type="ref"} and our in‐house database (*n* = 100).

WES analysis {#acn3551-sec-0010}
------------

We performed trio‐based WES for 17 families. Genomic DNA was captured using SureSelectXT Human All Exon V5 (50 Mb) or V6 (60 Mb) Kits (Agilent Technologies) and sequenced on a HiSeq2500 (Illumina) with 126‐base pair paired‐end reads. The reads were mapped to the hg19 human reference using Burrows‐Wheeler Aligner (BWA) 0.6.2‐r126[15](#acn3551-bib-0015){ref-type="ref"} and single‐nucleotide variants (SNVs), and insertions and/or deletions (indels) were called using the Genome Analysis Toolkit (GATK) v. 1.6--13.[16](#acn3551-bib-0016){ref-type="ref"} After quality filtering steps, variants were annotated using ANNOVAR.[17](#acn3551-bib-0017){ref-type="ref"} We prioritized the variants identified in enrolled CP patients as described below (Fig. [2](#acn3551-fig-0002){ref-type="fig"}). Nonsynonymous SNVs, splice‐site variants and indels were retained. We excluded variants present in the 1000 Genomes database, the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project (ESP6500), the Exome Aggregation Consortium (ExAC) database version 0.3 (all and East Asian populations), and the Human Genetic Variation Database (HGVD)[18](#acn3551-bib-0018){ref-type="ref"}, [19](#acn3551-bib-0019){ref-type="ref"} to discover rare de novo variants. For the autosomal recessive and X‐linked models, we excluded variants with an allele frequency equal to or greater than 1% in the 1000 Genomes database, the Exome Sequencing Project (ESP) 6500, the ExAC database version 0.3 (all and East Asian populations) and the HGVD. In the autosomal recessive and X‐linked models, autosomal variants with homozygotes found in the databases (or variants on the Chromosome X with hemizygotes in the databases) were filtered. Sorting intolerant from tolerant (SIFT),[20](#acn3551-bib-0020){ref-type="ref"} (polymorphism phenotypinb v2) PolyPhen2 HVAR,[21](#acn3551-bib-0021){ref-type="ref"} the Genomic Evolutionary Rate Profiling (GERP),[22](#acn3551-bib-0022){ref-type="ref"} and combined annotation‐dependent depletion (CADD)[23](#acn3551-bib-0023){ref-type="ref"} scores were used to predict nucleotide‐level conservation and the impact of amino acid substitutions. After extracting rare variants (listed in Table [S1](#acn3551-sup-0001){ref-type="supplementary-material"}), only the rare variants that were present in Online Mendelian Inheritance in Man (OMIM) linked to neurodevelopmental diseases were prioritized as candidate variants. Each candidate variant was interpreted according to the American College of Medical Genetics and Genomics (ACMG) standards and guidelines.[24](#acn3551-bib-0024){ref-type="ref"} All the candidate variants were validated by Sanger sequencing, and the primers used for Sanger sequencing are listed in Table [S2](#acn3551-sup-0002){ref-type="supplementary-material"}.

![Schematic map of variants filtering. Rare variants and candidate variants in this figure are shown in Table [S1](#acn3551-sup-0001){ref-type="supplementary-material"} and Table [2](#acn3551-tbl-0002){ref-type="table-wrap"}, respectively. GQ, genotype quality; AAR, alternative allele ratio; AR, autosomal recessive; XL, X‐linked; ACMG, the American College of Medical Genetics and Genomics\* "Databases" include the 1000 Genomes database (all and East Asian populations), the ESP6500, the ExAC database version 0.3 (all and East Asian populations) and the HGVD.](ACN3-5-538-g002){#acn3551-fig-0002}

Extraction of RNA and reverse transcription‐polymerase chain reaction (RT‐PCR) {#acn3551-sec-0011}
------------------------------------------------------------------------------

To demonstrate aberrant splicing of *CTNNB1* (case 3) and *AMPD2* (case 11) derived from each variant, whole blood was collected using a PAXgene RNA Blood RNA Kit (QIAGEN, Hilden, Germany) from each patient and two healthy controls. The RNA samples were extracted from fresh blood samples using a QIAamp RNA Blood Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturer\'s instructions. The cDNA was synthesized using a PrimeScript RT (reverse transcription) reagent Kit with gDNA Eraser (TaKaRa, Shiga, Japan) according to the manufacturer\'s instructions. *CTNNB1* and *AMPD2* cDNA were amplified using TaKaRa ExTaq Hot Start Version (TaKaRa, Shiga, Japan), followed by agarose gel electrophoresis and analyzed by bidirectional Sanger sequencing. The primers are listed in Table [S2](#acn3551-sup-0002){ref-type="supplementary-material"}.

AMP deaminase assay {#acn3551-sec-0012}
-------------------

White blood cells (WBCs) were extracted from the heparinized whole blood of two patients (case 3 and case 11) and two healthy volunteers to establish lymphoblastoid cell lines (LCLs) infected with Epstein--Barr virus (EBV) as previously described.[25](#acn3551-bib-0025){ref-type="ref"} AMPD2 enzyme activity in the WBCs was analyzed using these EBV‐infected LCLs (EBV‐LCLs). AMP deaminase activity in EBV‐LCL cells was assessed as previously described[26](#acn3551-bib-0026){ref-type="ref"} with minor modifications. Briefly, the cells were lysed in ice‐cold buffer A (250 mmol/L sucrose, 150 mmol/L KCl, 20 mmol/L imidazole HCl), and the protein concentration in the supernatant was measured with a Pierce BCA Protein Assay Kit (Thermo Scientific, Waltham, MA, USA). Extracts containing 2 *μ*g of total protein were mixed with 50 mmol/L sodium citrate (pH 7), 50 mmol/L KCl, and 4 mmol/L AMP. For each protein extract a reaction mixture without AMP was prepared for background quantification. After 1 hour of incubation at 25°C, 50 *μ*L of the previous reaction mixture and 100 *μ*L of reagent A (10 mmol/L phenol, 20 mmol/L sodium nitroprusside) were transferred to the wells of a 96‐well plate containing the previous reaction samples and 100 *μ*L of reagent B (12.5 mmol/L sodium hydroxide, 20 mmol/L dibasic sodium phosphate, 0.01% sodium hypochlorite) was then added. After 3 h of incubation at 25°C, the absorbance of the samples was measured at 625 nm using a SPECTRA Max 190 microplate reader (Molecular Devices, Sunnyvale, CA) against a reagent blank. An ammonia standard was prepared from ammonium sulfate to quantify the amount of ammonia formed by the cell extracts during incubation with AMP. To minimize variability in each experiment, the results were calculated from the ratio of absorbance in each sample to the average concentration in three control samples (case 3 and 2 healthy controls). Statistical analysis was performed using one‐way analysis of variance with a Dunnett\'s test for unequal variance.

Results {#acn3551-sec-0013}
=======

Characteristics of the participants {#acn3551-sec-0014}
-----------------------------------

A total of 17 cases and their parents were enrolled and analyzed, as shown in Figure [1](#acn3551-fig-0001){ref-type="fig"}. Overall, 11 participants were male (64.7%) with a median age of 9.5 years (range, 3--30 years) and all participants were Japanese and nonconsanguineous. The median age at diagnosis of CP and follow‐up period was 40 months (range, 16--178 months) and 84 months (range, 26--358 months), respectively. This case series was classified into four CP types: spastic diplegia (11, 64.7%), dyskinetic type (3, 17.6%), ataxic type (2, 11.8%), and mixed type (1, 5.9%). All exhibited sporadic onset under 2 years of age, and their condition was nonprogressive, which is compatible with the definition of CP.[1](#acn3551-bib-0001){ref-type="ref"} None of the family histories of the cases were significant. Only case 2 underwent neonatal resuscitation with mask‐bag ventilation. Ten cases (58.8%) had normal brain MRI findings, and the others had nonspecific findings. The nonspecific brain MRI findings are shown (Fig. [3](#acn3551-fig-0003){ref-type="fig"}). All cases except case 4 (94.1%) exhibited intellectual disability at the last follow‐up. The clinical characteristics of these cases are described in Table [1](#acn3551-tbl-0001){ref-type="table-wrap"} (see also Appendix [S1](#acn3551-sup-0002){ref-type="supplementary-material"}).

![Nonspecific brain findings on T2‐weighted MRI. (A) Case 5; mild hyperintensity of the deep white matter around the body of the left lateral ventricle. (B) Case 7; slight hyperintensity of the left pars triangularis. (C) Case 11; hyperintensity in the striatum and a thin corpus callosum. (D) Case 13; a thin corpus callosum and mildly enlarged lateral ventricle. (E) Case 14; a thin corpus callosum and cerebral white matter atrophy. (F) Case 16; slight bilateral hyperintensities in the pallidum.](ACN3-5-538-g003){#acn3551-fig-0003}

###### 

Clinical features of case series

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Gender   Age, y   Age at CP diagnosis, m   Follow ‐up period, m   CP type       GW   BW at birth (SD), g   HC at birth (SD), cm   Perinatal complications   Brain MRI findings            Intellectual disability   Epilepsy   Autistic features   Other comorbidities   GMFCS   MACS   CFCS
  ------ -------- -------- ------------------------ ---------------------- ------------- ---- --------------------- ---------------------- ------------------------- ----------------------------- ------------------------- ---------- ------------------- --------------------- ------- ------ ------
  1      M        8        23                       91                     D             40   3066 (−0.5)           34.0 (+0.5)            --                        Normal                        Yes                       No         No                  Optic nerve atrophy   5       5      3

  2      M        30       74                       358                    S             41   3310 (−0.3)           N/D                    Neonatal Resuscitation\   Normal                        Yes                       Yes        No                  Microcephaly          2       4      4
                                                                                                                                           MAS/PDA                                                                                                                                               

  3      M        7        58                       87                     S             40   3428 (+0.7)           35.0 (+1.1)            --                        Normal                        Yes                       No         No                  Hyperekplexia         4       3      3

  4      M        9        51                       63                     S             38   3208 (−0.4)           33.5 (−0.5)            --                        Normal                        No                        No         No                  --                    3       1      1

  5      M        22       38                       260                    S             37   2890 (−0.4)           32.5 (−0.5)            --                        DWMH                          Yes                       No         No                  --                    4       5      2

  6      M        7        30                       64                     S             37   3182 (+1.0)           N/D                    --                        Normal                        Yes                       No         No                  --                    2       1      1

  7      F        7        16                       81                     D             38   2780 (−0.6)           32.5 (−0.5)            --                        DWMH                          Yes                       No         No                  --                    5       5      4

  8      M        15       164                      26                     S             40   3120 (−0.5)           34.0 (−0.5)            --                        Normal                        Yes                       No         Yes                 Irritability          1       2      2

  9      F        13       116                      46                     AT            41   3548 (+1.3)           32.5 (−0.5)            --                        Normal                        Yes                       Yes        No                                        4       4      4

  10     M        8        26                       87                     S             40   3086 (+0.0)           33.0 (−0.3)            --                        Normal                        Yes                       No         No                  --                    4       3      2

  11     F        5        22                       51                     S             38   2554 (−0.6)           30.0 (−2.2)            --                        BG hyperintensityWM atrophy   Yes                       No         Yes                 Irritability          4       4      5

  12     F        3        31                       32                     AT            39   3134 (+0.4)           33.0 (−1.1)            −                         Normal                        Yes                       No         No                  Intention tremor      2       4      4

  13     M        10       40                       84                     S             40   3304 (+0.6)           31.8 (−1.2)            −                         WM atrophy                    Yes                       No         Yes                 −                     1       2      2

  14     F        22       27                       263                    S             40   2930 (−0.2)           31.5 (−1.4)            −                         Cortical atrophy              Yes                       Yes        No                  −                     4       4      5

  15     F        6        56                       82                     Mix (S, AT)   37   1736 (−2.6)           31.0 (−1.2)            SGA                       Normal                        Yes                       No         No                  VATER association     2       3      3

  16     M        11       25                       130                    D             37   3298 (+1.7)           35.5 (+2.1)            --                        BG hyperintensity             Yes                       No         No                  --                    4       3      3

  17     M        19       178                      76                     S             37   3094 (+1.1)           36.0 (+2.5)            --                        Normal                        Yes                       Yes        Yes                 Hemolysis             2       4      5
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CP, cerebral palsy; GW, gestational weeks; BW, birth weight; SD, standard deviation; HC, head circumference; MRI, magnetic resonance imaging; GMFCS, gross motor function classification; MACS, manual ability classification system; CFCS, communication function classification system; S, spastic diplegia; D, dyskinetic; AT, ataxic; N/D, no data; MAS, meconium aspiration syndrome; PDA, patent ductus arteriosus; SGA, small for gestational age; DWMH, Deep White matter hyperintensity; BG, basal ganglia; WM, white matter; ASD, autism spectrum disorder.

John Wiley & Sons, Ltd

aCGH analysis {#acn3551-sec-0015}
-------------

No CNVs were suspected to be pathogenically related to the phenotype of CP with aCGH. Only case 2 was identified as having X chromosome duplication and was confirmed to have XXY karyotypes in G‐banding, which is not closely related to CP.

WES analysis {#acn3551-sec-0016}
------------

The average mean depth was ×114. We obtained 17 clinically relevant candidate variants in 64.7% of the cases (11 of 17 cases) (Table [2](#acn3551-tbl-0002){ref-type="table-wrap"}). Of these cases, eight variants in seven cases within six genes: *CTNNB1*,*CYP2U1*,*SPAST*,*GNAO1*,*CACNA1A*, and *AMPD2*, were classified as pathogenic (41.2%) and the other two variants in two cases within two genes: *STXBP1* and *SCN2A* were likely pathogenic (11.8%) according to the ACMG standards and guidelines (Table [2](#acn3551-tbl-0002){ref-type="table-wrap"}). Most of the pathogenic/likely pathogenic variants identified in the nine cases were de novo (77.8%, 7 of 9). Two of the cases had autosomal recessive inheritance including one case of compound heterozygosity. One identified gene, *SPAST*, was found in two cases (case 6 and 10). Among the causative variants identified in the nine patients, the variants in *SPAST*,*GNAO1*,*CACNA1A,* and *STXBP1* have been previously reported,[27](#acn3551-bib-0027){ref-type="ref"}, [28](#acn3551-bib-0028){ref-type="ref"}, [29](#acn3551-bib-0029){ref-type="ref"}, [30](#acn3551-bib-0030){ref-type="ref"}, [31](#acn3551-bib-0031){ref-type="ref"}, [32](#acn3551-bib-0032){ref-type="ref"} whereas the variants in the other genes (*CTNNB1*,*CYP2U1*,*AMPD2*, and *SCN2A*) were novel. Of all the identified candidate genes, only *SPAST*,*STXBP1*, and *SPTBN2* have been previously reported in CP patients.[33](#acn3551-bib-0033){ref-type="ref"}, [34](#acn3551-bib-0034){ref-type="ref"}, [35](#acn3551-bib-0035){ref-type="ref"} In five cases, we identified eight unknown significant candidate variants of five genes (*UBA1*,*AMER1*,*FAT4*,*GPR98*, and *SPTBN2*). None of the variants except p.(Arg524Trp) in *SPTBN2* were associated with any evidence, such as functional analysis, previous reports, evolutionary conservation, or computational predictive programs, suggesting that they were a cause of disease. Thus, we did not pursue those candidate variants in this study.

###### 

Cases with pathogenic or potentially pathogenic variants identified by trio WES analysis and the result of aCGH analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case                                              CNVs       Gene             OMIM      OMIM disease                                 Previous report of CP   Inheritance                Position (hg19)         Effect on Protein    Protein change        Previously reported vaiant   SIFT score   Polyphen2 HVAR   CADD phred   GERP‐RS   ExAC      Pathogenicity
  ------------------------------------------------- ---------- ---------------- --------- -------------------------------------------- ----------------------- -------------------------- ----------------------- -------------------- --------------------- ---------------------------- ------------ ---------------- ------------ --------- --------- ---------------------
  Pathogenic/likely pathogenic candidate variants                                                                                                                                                                                                                                                                                                        

  3                                                 No         *CTNNB1*         114550    Intellectual disability                      No                      De novo                    Chr3:41275790 T \> C    Splice site change   p.Glu562AlafsTer11    No                           NA           NA               22.9         5.66      0         Pathogenic

  5                                                 No         *CYP2U1*         610670    Spastic paraplegia                           No                      AR‐homozygous              Chr4:108866283 del C    Frame shift          p.(Phe218fsTer42)     No                           NA           NA               NA           NA        0         Pathogenic

  6                                                 No         *SPAST*          604277    Spastic paraplegia                           Yes                     De novo                    Chr2:32361662 C \> T    Missense             p.(Leu426Phe)         Yes                          0.002        0.999            32           5.62      0         Pathogenic

  7                                                 No         *GNAO1*          139311    EIEE                                         No                      De novo                    Chr16:56385308 G \> A   Missense             p.(Glu246Lys)         Yes                          0            1                22.7         5.91      0         Pathogenic

  9                                                 No         *CACNA1A*        601011    Spinocerebellar ataxia EIEE                  No                      De novo                    Chr19:13476262 G \> A   Missense             p.(Ser218Leu)         Yes                          0.002        0.998            33           5.55      0         Pathogenic

  10                                                No         *SPAST*          604277    Spastic paraplegia                           Yes                     De novo                    Chr2:32366975 G \> A    Missense             p.(Arg499His)         Yes                          0            1                34           4.98      0         Pathogenic

  11                                                No         *AMPD2*          102771    Spastic paraplegia\                          No                      AR‐Compound heterozygous   Chr1:110168415 G \> A   Splice site change   p.Leu173Ter           No                           NA           NA               25.9         4.59      0         Pathogenic
                                                                                          Pontocerebellar hypoplasia                                                                                                                                                                                                                                     

  Chr1:110171419 C \> T                             Missense   p.(Pro456Leu)    No        0                                            1                       34                         5.08                    0                    Pathogenic                                                                                                        

  12                                                No         *STXBP1*         612164    EIEE                                         Yes                     De novo                    Chr9:130428484 C \> G   Missense             p.(Arg235Gly)         Yes                          0            1                34           5.72      0         Likely Pathogenic

  17                                                No         *SCN2A*          607745    EIEE                                         No                      De novo                    Chr2:166245610 T \> C   Missense             p.(Leu1765Pro)        No                           0            1                25.6         5.72      0         Likely Pathogenic

  Unknown significance candidate variants                                                                                                                                                                                                                                                                                                                

  2                                                 dupX       *UBA1*           301830    Spinal muscular atrophy                      No                      X‐linked                   ChrX:47069086 C \> T    Missense             p.(Thr668Ile)         No                           0.05         0.003            16.1         5.22      0         Unknown\
                                                                                                                                                                                                                                                                                                                                                         Significance

  6                                                 No         *AMER1*          3006471   Osteopathia striata with cranial sclerosis   No                      X‐linked                   ChrX:63412347 G \> A    Missense             p.(Pro274Ser)         No                           0.07         0.001            0.61         0.174     0.00001   UnknownSignificance

  7                                                 No         *FAT4*           615546    Van Maldergem syndrome                       No                      Compound heterozygous      Chr4:126238810 C \> G   Missense             p.(Pro415Arg)         No                           0.18         1                18.22        4.55      0.0002    Unknown\
                                                                                                                                                                                                                                                                                                                                                         Significance

  Chr4:126411082 A \> G                             Missense   p.(Met4370Val)   No        1                                            0                       0.027                      0.09                    0.0012               Unknown\                                                                                                          
                                                                                                                                                                                                                                       Significance                                                                                                      

  15                                                No         *GPR98*          602851    Usher syndrome type2C                        No                      Compound heterozygous      Chr5:89979443 A \> G    Missense             p.(His1902Arg)        No                           0.32         0                9.526        −0.074    0         Unknown\
                                                                                                                                                                                                                                                                                                                                                         Significance

  Chr5:90086965 A \> G                              Missense   p.(Ile4773Met)   No        0.095                                        0.859                   21.5                       −10.8                   0.0001               UnknownSignificance                                                                                               

  17                                                No         *SPTBN2*         604985    Spinocerebellar ataxia                       Yes                     Compound heterozygous      Chr11:66455748 C \> T   Missense             p.(Arg2089Lys)        No                           0.443        0.009            0.037        −6.45     0.0002    Unknown\
                                                                                                                                                                                                                                                                                                                                                         Significance

  Chr11:66475070 G \> A                             Missense   p.(Arg524Trp)    No        0                                            1                       34                         4.47                    0                    Unknown\                                                                                                          
                                                                                                                                                                                                                                       Significance                                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CNV, copy number variation; OMIM, Online Mendelian Inheritance in Man; CP, cerebral palsy; dupX, duplicate X chromosome; AR, autosomal recessive; EIEE, early infantile epileptic encephalopathy; NA, not applicable.
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cDNA analysis {#acn3551-sec-0017}
-------------

We identified two splicing candidate variants (*CTNNB1*, Chr3: 41275790 T \> C and *AMPD2*, Chr1: 110168415 G \> A) in case 3 and case 11, respectively. We explored the effect of these variants on mRNA transcription using reverse transcription polymerase chain reaction (RT‐PCR). We obtained each wild‐type transcript and aberrant transcripts (Fig. [4](#acn3551-fig-0004){ref-type="fig"}). Sequence analysis of these cDNAs showed that translation of each aberrant transcript would have catenin beta‐1 and AMP deaminase 2 prematurely terminated. The variant in case 3 of *CTNNB1* resulted in a frameshift followed by a premature termination at codon 572 of the mutant protein, which was preceded by an abnormal sequence of 10 amino acids (p.Glu562AlafsTer11) (Fig. [4](#acn3551-fig-0004){ref-type="fig"}A and B). Another variant in case 11 of *AMPD2* also resulted in a premature termination at codon 216, which is the position immediately after the variant (Fig. [4](#acn3551-fig-0004){ref-type="fig"}C and D). These results support the pathogenicity of each variant.

![Analysis of the splice‐site variant of *CTNNB1* in case 3 and *AMPD2* in case 11. (A) RT‐PCR product of partial *CTNNB1* run on 2% agarose gel electrophoresis. RT‐PCR products obtained from RNA of peripheral blood lymphocytes. (B) *CTNNB1* sequence analysis of cDNA. The locations and corresponding cDNA sequencing results focusing on the exon 10--11 junction in the wild‐type (top) and *CTNNB1* mutant cDNA (bottom) obtained from RT‐PCR. The corresponding translated amino acid sequences for the actual and hypothetical mutant products are also shown. The locations of the variants and stop codons are marked in the mutant diagram. (C) RT‐PCR product of partial *AMPD2* from electrophoresis. (D) *AMPD2* sequence analysis of cDNA. The locations and corresponding cDNA sequencing results focusing on the exon 4--5 junction in the wild‐type (top) and *AMPD2* mutant cDNA (bottom) obtained from RT‐PCR. The corresponding translated amino acid sequences for the actual and hypothetical mutant products are also shown. The locations of the variant and stop codons are marked in the mutant diagram. bp, base pair; MW, molecular weight; NC, negative control; Ctr, control.](ACN3-5-538-g004){#acn3551-fig-0004}

AMP deaminase assay {#acn3551-sec-0018}
-------------------

*AMPD2* encodes one of three known AMP deaminase homologues, which convert AMP to IMP, and is necessary for guanine nucleotide biosynthesis and protein translation.[26](#acn3551-bib-0026){ref-type="ref"} To validate the pathogenicity of *AMPD2* compound heterozygous variants in case 11, we performed an AMP deaminase activity assay. We found a significant reduction in AMP deaminase activity by approximately 60% in EBV‐LCL case 11 compared to two healthy controls and case 3 (Fig. [5](#acn3551-fig-0005){ref-type="fig"}A and B).

![AMP deaminase assay. (A) Blue intensity represents relative activity. NC, Negative control; Ctr, Control. (B) Quantification of relative absorbance ± SD for six independent experiments measured at 625 nm. \**P* \< 0.001. a Dunnett\'s test for unequal variance.](ACN3-5-538-g005){#acn3551-fig-0005}

Discussion {#acn3551-sec-0019}
==========

A comprehensive genomic analysis by aCGH and trio WES was performed in 17 unexplained CP patients without a history of preterm delivery or specific MRI findings. We found that nine patients (52.9%) had pathogenic/likely pathogenic variants according to the ACMG guidelines and that these variants were de novo in seven patients and recessively inherited in two patients. The gene identified in eight CP masqueraders consisted of three hereditary spastic paraplegia (HSP) genes (*CYP2U1*,*SPAST*, and *AMPD2*), four genes associated with early infantile epileptic encephalopathy (EIEE) and neurodevelopmental diseases (*SCN2A*,*CACNA1A*,*GNAO1*, and *STXBP1*) and one other gene (*CTNNB1*). We confirmed the pathogenicity of two splice‐site variants in *AMPD2* and *CTNNB1* and one missense variant in *AMPD2* using in vitro functional analysis. In a previous report, candidate variants were identified in 14 of 98 unselected CP patients (14.3%),[2](#acn3551-bib-0002){ref-type="ref"} indicating that our detection rate was significantly higher (*P* \< 0.005, Fisher\'s exact test). Furthermore, if the variants of the previous study had been prioritized according to the ACMG guidelines and only genes known to be relevant to neurodevelopmental disorders were retained, the detection rate of candidate pathogenic/likely pathogenic genes for CP would have decreased to 4% (4 in 98 patients), contributing to an even larger difference compared to our study. Therefore, full‐term CP includes more masqueraders than the general population of CP patients, which suggests that efficient genetic testing can be developed for full‐term CP patients using trio WES analysis. Moreover, similar result have been reported by a recent study, according to which 11 of 78 patients with neurodevelopmental disorders diagnosed using WES exhibited CP‐like syndrome.[35](#acn3551-bib-0035){ref-type="ref"}

No significant pathogenic CNVs were identified with aCGH in this study, unlike other previous reports,[3](#acn3551-bib-0003){ref-type="ref"}, [36](#acn3551-bib-0036){ref-type="ref"} in which pathogenic CNVs were identified in 9.6--31% of patients with aCGH. This wide range of proportions could be explained by variations in case selection or differences in the criteria used to evaluate pathogenicity. A high rate of pathologic CNVs (16%) was reported in children who were born small for their gestational age (SGA) with a persistent short stature.[37](#acn3551-bib-0037){ref-type="ref"} SGA patients enrolled in the previous CP cohorts may have contributed to the higher detection rate of CNVs compared to our CP cohorts, which contained only one SGA patient. Our findings indicate that the diagnostic yield of aCGH may be low in full‐term CP; however, further research with a larger sample is needed for establishing recommendations for the diagnostic testing strategy.

We identified candidate pathogenic variants of three genes known to cause HSP in four patients (*CYP2U1* in case 5; *SPAST* in cases 6 and 10; and *AMPD2* in case 11). HSP is a heterogeneous neurological disorder characterized by progressive spasticity and weakness of the lower limbs.[38](#acn3551-bib-0038){ref-type="ref"} To date, 55 HSP genes have been identified. HSP is clinically classified as either the pure form or complicated form, the latter of which is associated with additional neurological features such as ataxia, intellectual disability, neuropathy, and epilepsy.[38](#acn3551-bib-0038){ref-type="ref"} Present cases (case 5, 6, 10, and 11) all showed nonprogressive spastic diplegia during an extended follow‐up period (range, 51--260 months), which is consistent with criteria for CP but not HSP.[1](#acn3551-bib-0001){ref-type="ref"}, [38](#acn3551-bib-0038){ref-type="ref"} This suggests that these HSP genes can cause not only HSP, but also the spastic type of CP masqueraders. A homozygous nonsense variant was identified in case 5 in *CYP2U1*, which was reported to cause SPG56.[38](#acn3551-bib-0038){ref-type="ref"} Symptoms of case 5 included intellectual disability and spastic diplegia, which resembled the phenotype of SPG56.[38](#acn3551-bib-0038){ref-type="ref"} In cases 6 and 10, we found two known de novo variants in *SPAST*,[27](#acn3551-bib-0027){ref-type="ref"}, [28](#acn3551-bib-0028){ref-type="ref"} which is the most commonly mutated gene (SPG4) in HSP.[37](#acn3551-bib-0037){ref-type="ref"} Cases 6 and 10 developed a mild form of spastic diplegia, which was consistent with the severity of other patients who had variants in *SPAST*. Case 11 had compound heterozygous variants and low deaminase activity in her EBV‐LCL cells. A frameshift *AMPD2* variant was recently identified in a patient with complicated HSP,[39](#acn3551-bib-0039){ref-type="ref"} whereas *AMPD2* variants were mainly reported in pontocerebellar hypoplasia.[26](#acn3551-bib-0026){ref-type="ref"} Our results, together with a previous report, extend the phenotypic spectrum of *AMPD2* variants (see Appendix [S1](#acn3551-sup-0002){ref-type="supplementary-material"}).

Four candidate pathogenic/likely pathogenic variants of genes for EIEE and neurodevelopmental diseases were identified in four patients, including *GNAO1* in case 7, *CACNA1A* in case 9, *STXBP1* in case 12, and *SCN2A* in case 17. *GNAO1* variants cause both EIEE and neurodevelopmental disorders,[29](#acn3551-bib-0029){ref-type="ref"} which manifested in case 7 as an intellectual disability, although no seizures occurred. We identified p.(Ser218Leu) variants in case 9, diagnosed as ataxic CP. The p.Phe1502del variant of *CACNA1A* has been reported to cause congenital ataxia, which has similar characteristics to case 9.[40](#acn3551-bib-0040){ref-type="ref"} *CACNA1A* variants cause various neuropsychiatric diseases. The p.(Ser218Leu) variant has also been associated with familial hemiplegic migraines and cerebellar ataxia,[30](#acn3551-bib-0030){ref-type="ref"} as well as EIEE.[31](#acn3551-bib-0031){ref-type="ref"} If the cerebellar ataxia develops congenitally and appears stable, it may be due to ataxic CP masqueraders, as in case 9. *STXBP1* has been primarily reported to be a causative gene for EIEE. Additionally, various phenotypic features were recently described, including autistic features, spasticity, hypotonia, ataxia, and dyskinesia. Because approximately 5% of patients with variants of *STXBP1* do not have seizures and a patient with the same variant as that in case 12 has been reported to show similar phenotypic symptoms, including ataxia, wide‐based gait, intention tremor, and intellectual disability without epilepsy,[32](#acn3551-bib-0032){ref-type="ref"} it is likely that candidate variant in *STXBP1* caused ataxic CP with such phenotype in case 12. Some patients with *SCN2A* variants show intellectual disability, autistic behaviors, involuntary movement, and lower limb spasticity in addition to epilepsy,[41](#acn3551-bib-0041){ref-type="ref"} which explains the symptoms of case 17. Furthermore, case 17 was also a compound heterozygote of *SPTBN2* variants. *SPTBN2* has been identified in both autosomal dominant and autosomal recessive spinocerebellar ataxia,[42](#acn3551-bib-0042){ref-type="ref"} together with CP.[34](#acn3551-bib-0034){ref-type="ref"} Although both *SPTBN2* variants in case 17 were classified as having uncertain significance and the patient\'s clinical presentation was consistent with *SCN2A*‐related disorder, we cannot eliminate the possibility that those variants in *SPTNBN2* could contribute to the patient\'s phenotype. In addition to genes for HSP and EIEE/neurodevelopmental disorders, we identified a variant of *CTNNB1* in case 3. Although the variants of *CTNNB1* have been reported to cause autosomal dominant mental retardation type 19, most of the patients with this variant show signs of other clinical features, including progressive spastic diplegia, hypotonia, microcephaly, craniofacial abnormalities, and hyperekplexia.[43](#acn3551-bib-0043){ref-type="ref"} Case 3 had intellectual disability and spastic diplegia with hyperekplexia, which corresponded with the phenotype for *CTNNB1*‐related diseases.

Although the phenotypes are quite similar to CP, six of the eight genes identified as having candidate pathogenic/likely pathogenic variants (*CTNNB1*,*CYP2U1*,*GNAO1*,*CACNA1A*,*AMPD2*, and *SCN2A*) have not been reported to be the causative genes of CP potentially because they do not fit the definition of CP, such as the presence of regression or an older age onset. Therefore, these gene variants may be found in a wide clinical spectrum of neurodevelopmental diseases, such as HSP, complicated forms of intellectual disability, EIEE, and CP masqueraders.

The identification of the causative genes may affect patient management. For example, deep brain stimulation has been reported to have successfully improved movement disorder in two siblings with the *GNAO1* variant.[44](#acn3551-bib-0044){ref-type="ref"} In addition to the case report, the patient of case 7 can be treated using deep brain stimulation. Moreover, spinocerebellar ataxia type 6, caused by the same causative gene (*CACNA1A*) as that in case 9, could be potentially treated using the miRNA‐mediated therapy in the future, as was reported in the mouse model.[45](#acn3551-bib-0045){ref-type="ref"}

There are certain limitations of this study. First, the sample size was small in this highly selected case series. Although the yield in this study was significantly higher than that reported in unselected CP patients,[2](#acn3551-bib-0002){ref-type="ref"} our interpretation is limited because no comparison was made with the general CP population. As recent studies have not reported information on gestational ages or brain MRI of patients,[2](#acn3551-bib-0002){ref-type="ref"} we were not able to find CP patients who met our criteria to calculate a diagnostic yield for comparison with our results. Second, there are some gaps between the CP phenotype in this case series and that identified in their variants or genes. Functional validations were not performed in all known or pathogenic/likely pathogenic variants identified in this study. Moreover, functional experiments in the animal model and the identification of other patients with the same phenotype and gene are necessary to confirm our results. A lack of such validation leaves the possibility that those gene variants are not a monogenic cause, rather a contributor to the multifactorial disease, although these variants were prioritized following the ACMG guidelines. Third, the small sample size in our cohort also limited statistical comparisons between the genetic and clinical findings, including CP subtypes and intellectual disability. In terms of CP subtypes, four of the six patients with spasticity contained the variants in genes (*CYP2U1*,*SPAST*, and *AMPD2*) known to cause spastic paraplegia, while the other two contained the variants in genes (*CTNNB1* and *SCN2A*) known to cause other neurodevelopmental disorders. Both genes have not been reported to cause spastic CP; however, the spasticity of patients has been reported previously.[32](#acn3551-bib-0032){ref-type="ref"}, [41](#acn3551-bib-0041){ref-type="ref"} The patients with other CP subtypes, including ataxic type and dyskinetic type, showed no tendency toward spastic diplegia. With respect to intellectual disability, the morbidity was higher (16/17, 94.1%) than previously reported (77.5%),[46](#acn3551-bib-0046){ref-type="ref"} suggesting a representative feature of our cohort, although it is challenging to accurately measure the intellectual disability,[47](#acn3551-bib-0047){ref-type="ref"} and this margin is insignificant owing to the small sample size. Larger CP cohort analyses including full‐term and preterm infants with diverse datasets (e.g., the Apgar score) classified using the brain MRI findings (normal to extensive abnormality, such as PVL) are needed to clarify the genetic epidemiology of CP and CP masqueraders.

In summary, our study showed the possibility that a subset of CP patients categorized by two simple criteria include CP masqueraders despite several limitations. Further genetic investigations of larger cohorts of CP patients are required to help support our results or identify other CP subsets that may likely include masqueraders. This could eventually aid the further characterization of the molecular mechanisms of CP and clinically similar disorders.
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